Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

被引：0
|
作者：
Stilgenbauer, Stephan [1 ]
Morschhauser, Franck [2 ]
Wendtner, Clemens-Martin [3 ]
Cartron, Guillaume [4 ]
Hallek, Michael [5 ,6 ]
Eichhorst, Barbara [7 ]
Kozloff, Mark F. [8 ]
Giever, Thomas [9 ]
Lozanski, Gerard [10 ]
Jiang, Yanwen [11 ]
Huang, Huang [12 ]
Pignataro, Daniela Soriano [13 ]
Schary, William [14 ]
Humphrey, Kathryn [15 ]
Mobasher, Mehrdad [11 ]
Salles, Gilles [16 ]
机构：
[1] Ulm Univ, Dept Internal Med 3, Ulm, Germany
[2] Univ Lille 2, Ctr Hosp Univ, Hematol, Lille, France
[3] Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany
[4] Univ Hosp Montpellier, Dept Clin Hematol, Montpellier, France
[5] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[6] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany
[7] Univ Cologne, Dept Internal Med 1, Cologne, Germany
[8] Univ Chicago Med, Chicago, IL USA
[9] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[10] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[13] Roche Prod Ltd, Welwyn Garden City, Herts, England
[14] AbbVie, N Chicago, IL USA
[15] Roche Prod Ltd, Welwyn Garden City, Herts, England
[16] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, CHU Lyon Sud, Dept Hematol, Pierre Benite, France
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-118362
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1859
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A Phase 2 Study of Alemtuzumab-Ofatumumab (A plus O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update
    Lundin, Jeanette
    Rosen, Steven T.
    Osterborg, Anders
    Frankfurt, Olga
    Winter, Jane N.
    Rademaker, Alfred
    Kreutzer, Jennifer
    Bacon, Elizabeth
    Sonnert-Husa, Sonja
    Ma, Shuo
    BLOOD, 2015, 126 (23)
  • [42] GREEN study: preliminary safety results from a phase IIIb trial of obinutuzumab alone or in combination with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia
    Bosch, Francesc
    Knauf, Wolfgang
    Robinson, Sue
    Montillo, Marco
    Dilhuydy, Marie-Sarah
    Mendoza, Maria
    Bernhardt, Alf
    Lasserre, Susan
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA & LYMPHOMA, 2015, 56 : 141 - 143
  • [43] Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Lozanski, Gerard
    Little, Richard
    Ding, Wei
    Hill, Brian T.
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2019, 134
  • [44] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [45] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
  • [46] Safety of Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Primary Analysis of the Phase 3b GREEN Study
    Stilgenbauer, Stephan
    Aktan, Melih
    Coll, Christelle M. Ferra
    Dartigeas, Caroline
    Kisro, Jens
    Montillo, Marco
    Raposo, Joao
    Merot, Jean-Louis
    Robson, Susan
    Gresko, Ekaterina
    Bosch, Francesc
    Foa, Robin
    Leblond, Veronique
    BLOOD, 2017, 130
  • [47] Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
    Flinn, Ian W.
    Berdeja, Jesus G.
    Waselenko, Jamie K.
    Cooper, R. Seth
    Bi, Jia
    Shih, Kent
    Doss, Habib H.
    Dickson, Natalie
    Thompson, Dana S.
    Burris, Howard A., III
    Hainsworth, John D.
    BLOOD, 2010, 116 (21) : 1022 - 1022
  • [48] Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study
    Ysebaert, Loic
    Troussard, Xavier
    Levy, Vincent
    Le Calloch, Ronan
    Guieze, Romain
    Laribi, Kamel
    Lepretre, Stephane
    Michallet, Anne-Sophie
    Leblond, Veronique
    Feugier, Pierre
    Lahjibi, Elhem
    Ramier, Julien
    Delmer, Alain
    BLOOD, 2022, 140 : 12395 - 12396
  • [49] Fixed-Duration Venetoclax-Obinutuzumab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: Follow-Up of Efficacy and Safety Results From the Multicenter, Open-Label, Randomized, Phase III CLL14 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 11 - 11
  • [50] Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
    Al-Sawaf, Othman
    Zhang, Can
    Tandon, Maneesh
    Sinha, Arijit
    Fink, Anna-Maria
    Robrecht, Sandra
    Samoylova, Olga
    Liberati, Anna M.
    Pinilla-Ibarz, Javier
    Opat, Stephen
    Sivcheva, Liliya
    Le Du, Katell
    Fogliatto, Laura M.
    Niemann, Carsten U.
    Weinkove, Robert
    Robinson, Sue
    Kipps, Thomas J.
    Tausch, Eugen
    Schary, William
    Ritgen, Matthias
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    LANCET ONCOLOGY, 2020, 21 (09): : 1188 - 1200
12345